OMER Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Omeros Corp (OMER) is not a strong buy for a beginner, long-term investor at this moment. While there are positive catalysts such as hedge fund interest and a recent price target increase by analysts, the company's financial performance is weak, and technical indicators do not suggest a strong entry point. Additionally, the absence of recent news, congress trading data, and proprietary trading signals further reduces confidence in an immediate buy decision.
The MACD is negatively expanding (-0.108), RSI is neutral at 29.403, and moving averages are converging, indicating no clear trend. The stock is trading below its pivot point (10.86), with key support at 10.224 and resistance at 11.496. Short-term technicals suggest a lack of momentum for a strong upward move.
Hedge funds are significantly increasing their positions in the stock (185085.19% increase in buying). Analysts have raised the price target to $40, citing the approval of Yartemlea as a critical inflection point.
No recent news or congress trading data. Weak financial performance with declining net income (-4.08% YoY) and EPS (-16.07% YoY). Technical indicators do not show a strong buy signal.
In Q3 2025, revenue remained stagnant at $0, net income dropped to -$30.92 million (-4.08% YoY), and EPS fell to -0.47 (-16.07% YoY). Gross margin also remained at 0%. Overall, financials show no growth and declining profitability.
H.C. Wainwright analyst Brandon Folkes raised the price target to $40 from $20 and maintained a Buy rating, citing the approval of Yartemlea as a critical milestone for the company.
